Document is current
Any future updates will be listed below
-
Authors
Pfeuffer, Nicola https://orcid.org/0009-0007-2171-5602
Hartmann, Fabian https://orcid.org/0000-0001-6106-1657
Grahammer, Manuel https://orcid.org/0000-0003-1560-4459
Simon, David https://orcid.org/0000-0001-8310-7820
Schuster, Louis https://orcid.org/0000-0002-5878-8465
Kuhn, Sebastian https://orcid.org/0000-0002-8031-2973
Krönke, Gerhard https://orcid.org/0000-0002-7566-4325
Schett, Georg https://orcid.org/0000-0001-8740-9615
Knitza, Johannes https://orcid.org/0000-0001-9695-0657
Kleyer, Arnd https://orcid.org/0000-0002-2026-7728
-
Funding
Funding for this research was provided by:
Philipps-Universität Marburg
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 18 January 2025
First Online: 4 February 2025
Declarations
:
: The trial was approved by the Ethics Committee of the University Hospital Erlangen-Nuremberg (Reg no. 333_16B on 7th of December 2016 and 21_21B on 2nd of March 2021). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual respondents included in the study.
: MG: Founder and CEO of ABATON. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
